{
    "root": "2fbb57c5-df02-59ea-e063-6394a90a59c4",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "AMOXICILLIN AND CLAVULANATE POTASSIUM",
    "value": "20250307",
    "ingredients": [
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "XANTHAN GUM",
            "code": "TTV12P4NEE"
        },
        {
            "name": "ASPARTAME",
            "code": "Z0H242BBR1"
        },
        {
            "name": "CARBOXYMETHYLCELLULOSE SODIUM",
            "code": "K679OBS311"
        },
        {
            "name": "AMOXICILLIN",
            "code": "804826J2HU"
        },
        {
            "name": "CLAVULANATE POTASSIUM",
            "code": "Q42OMW3AT8"
        }
    ],
    "indications": "amoxicillin clavulanate potassium indicated treatment pediatric patients recurrent persistent acute otitis media due s. pneumoniae ( penicillin mics less equal 2 mcg/ml ) , h. influenzae ( including β-lactamase-producing strains ) , m. catarrhalis ( including β-lactamase-producing strains ) characterized following risk factors : - antibacterial exposure acute otitis media within preceding 3 months , either following : 1 ) age 2 years , younger 2 ) daycare attendance [ microbiology ( 12.4 ) ] limitations acute otitis media due s. pneumoniaealone treated amoxicillin . amoxicillin clavulanate potassium oral suspension indicated treatment acute otitis media due s. pneumoniaewith penicillin mic greater equal 4 mcg/ml . therapy may instituted prior obtaining results bacteriological reason believe infection may involve s. pneumoniae ( penicillin mic less equal 2 mcg/ml ) β-lactamase-producing organisms listed . usage reduce development drug-resistant bacteria maintain effectiveness amoxicillin clavulanate potassium oral suspension antibacterial drugs , amoxicillin clavulanate potassium oral suspension used treat prevent infections proven strongly suspected caused susceptible bacteria . culture susceptibility information available , considered selecting modifying antibacterial therapy . absence data , local epidemiology susceptibility patterns may contribute empiric selection therapy .",
    "contraindications": "pediatric patients less 40 kg : 90 mg/kg/day divided every 12 hours , administered 10 days . ( 2 )",
    "warningsAndPrecautions": null,
    "adverseReactions": "history serious hypersensitivity reaction ( e.g . , anaphylaxis stevens-johnson syndrome ) amoxicillin clavulanate potassium oral suspension beta-lactams ( e.g . , penicillins cephalosporins ) . ( 4.1 ) history cholestatic jaundice/hepatic dysfunction associated amoxicillin clavulanate potassium oral suspension . ( 4.2 )",
    "indications_original": "Amoxicillin and Clavulanate Potassium is indicated for the treatment of pediatric patients with\n                  \n                  \n                     Recurrent or persistent acute otitis media due to\n  \n   S. pneumoniae(penicillin MICs less than or equal to 2 mcg/mL),\n  \n   H. influenzae(including β-lactamase-producing strains), or\n  \n   M. catarrhalis(including β-lactamase-producing strains) characterized by the following risk factors:\n \n  \n                  \n                       - Antibacterial drug exposure for acute otitis media within the preceding 3 months, and either of the following: 1) age 2 years, or younger or 2) daycare attendance \n \n  [see Microbiology (\n  \n   12.4)]\n \n  \n                  \n                  \n                  \n                     Limitations of Use\n                  \n                  Acute otitis media due to\n \n  S. pneumoniaealone can be treated with amoxicillin. Amoxicillin and Clavulanate Potassium for oral suspension is not indicated for the treatment of acute otitis media due to\n \n  S. pneumoniaewith penicillin MIC greater than or equal to 4 mcg/mL. Therapy may be instituted prior to obtaining the results from bacteriological studies when there is reason to believe the infection may involve both\n \n  S. pneumoniae(penicillin MIC less than or equal to 2 mcg/mL) and the β-lactamase-producing organisms listed above.\n\n \n                  \n                  \n                     Usage\n                  \n                  To reduce the development of drug-resistant bacteria and maintain the effectiveness of Amoxicillin and Clavulanate Potassium for oral suspension and other antibacterial drugs, Amoxicillin and Clavulanate Potassium  for oral suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.",
    "contraindications_original": "Pediatric Patients less than 40 kg: 90 mg/kg/day divided every 12 hours, administered for 10 days. ( 2 )",
    "adverseReactions_original": "History of a serious hypersensitivity reaction (e.g., anaphylaxis or Stevens-Johnson syndrome) to Amoxicillin and Clavulanate Potassium for oral suspension or any other beta-lactams (e.g., penicillins or cephalosporins). ( 4.1 ) History of cholestatic jaundice/hepatic dysfunction associated with Amoxicillin and Clavulanate Potassium for oral suspension. ( 4.2 )"
}